Susan Kraus
Psychiatric/Mental Health · Towson, MDNPI 1316991706
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,375 of the $15,712 with a category attached, or 78.8%. AbbVie accounts for 93.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $5,901 and has fallen 99.0% since, to $60 in 2025. Among psychiatric/mental health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 148 payments — averaging $106.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$15K
- Sunovion Pharmaceuticals Inc.$193
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$140
- Lundbeck LLC$114
- Otsuka America Pharmaceutical, Inc.$105
- Teva Pharmaceuticals USA, Inc.$90
- plus $373 from 6 others
What the payments were for
- Speaking & faculty fees$12,37579%
- Travel & lodging$1,4039%
- Food & beverage$1,82412%
- Education$1101%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 94 | $14,698 |
| Sunovion Pharmaceuticals Inc. | 13 | $193 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $140 |
| Lundbeck LLC | 6 | $114 |
| Otsuka America Pharmaceutical, Inc. | 7 | $105 |
| Teva Pharmaceuticals USA, Inc. | 5 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $89 |
| Johnson & Johnson | 3 | $72 |
| Alkermes, Inc. | 3 | $71 |
| Idorsia Pharmaceuticals US Inc | 3 | $52 |
| Neurocrine Biosciences, Inc. | 3 | $47 |
| GSK | 3 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$13,578
How this compares
$15,712 in reported general payments places this provider in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $92,903 |
| RexultiBrexpiprazole | 27 | $60,872 |
| VraylarCariprazine Hcl | 29 | $59,520 |
| TrintellixVortioxetine Hydrobromide | 19 | $13,550 |
| Lurasidone Hcl | 54 | $11,568 |
| Asenapine Maleate | 19 | $5,623 |
| Duloxetine Hcl | 87 | $3,968 |
| Olanzapine OdtOlanzapine | 13 | $3,868 |
| Carbamazepine ErCarbamazepine | 16 | $3,735 |
| Divalproex Sodium | 80 | $2,847 |
| Escitalopram Oxalate | 97 | $2,536 |
| Bupropion XlBupropion Hcl | 63 | $2,496 |
| Aripiprazole | 76 | $2,291 |
| Lamotrigine | 112 | $1,828 |
| Clonazepam | 184 | $1,749 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $47 | $92,90311 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $105 | $60,87227 claims |
| AbbVieVraylar | $14,698 | $59,52029 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $89 | $13,55019 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $90 | $54613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Other psychiatric/mental health in Towson
- Victoria MojibolaTowson$6K
- Samantha RogersTowson$5K
- Hara OyedejiOwings Mills$780K
- Ilya RozenbergGlen Burnie$572K
- Michelle WilliamsColumbia$158K
- Kristin ClemensGaithersburg$36K
- Antonio HeroldHavre de Grace$23K
- Paul KlaverweidenFruitland$17K
- Margaret WebbAberdeen$16K
- Anyinke AtabongRockville$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.